Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424710 | 0.88 | L3MBTL1 (0.48) | SMN1; SMN2MAPTALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2305803 | 0.85 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17560242 | 0.84 | POLB (0.44) | TDP1SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL89866 | 0.84 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31444462 | 0.83 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL426830 | 0.83 | TUBB4A (0.55) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19329161 | 0.83 | POLB (0.42) | TDP1SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL2232809 | 0.83 | CNR1 (0.41) | HTTCNR1L3MBTL1MAPK1NPC1 | |
| SCHEMBL2714081 | 0.82 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL671972 | 0.82 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426350-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-30 | — | — | EP | disclosed |
| EP-3426350-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-30 | — | — | EP | disclosed |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2020-08-18 | — | — | US | disclosed |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2020-08-18 | — | — | US | disclosed |
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-02-06 | — | — | US | disclosed |
| EP-3426350-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153521-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153521-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| EP-2417121-A1 | 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | Pfizer Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBG2, HCCS | TUBB4A 876/4885TUBB 657/4885TUBA3C 1528/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | TUBB4A 3052/4885TUBB 3105/4885TUBA3C 3673/4885 |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HCCS | TUBB4A 876/4885TUBB 657/4885TUBA3C 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.